Drug Type Biosimilar, Monoclonal antibody |
Synonyms Han Li Kang, Recombinant Human/Murine Chimeric Anti-CD20 Monoclonal Antibody, 利妥昔单抗 (复宏汉霖) + [5] |
Target |
Action inhibitors |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), Complement dependent cytotoxicity (CDC) effects |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date China (22 Feb 2019), |
Regulation- |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Rheumatoid Arthritis | China | 23 Feb 2022 | |
| Rheumatoid Arthritis | China | 23 Feb 2022 | |
| Lymphoid Leukemia | China | 14 Jul 2020 | |
| Diffuse Large B-Cell Lymphoma | China | 22 Feb 2019 | |
| Follicular Lymphoma | China | 22 Feb 2019 | |
| Non-Hodgkin Lymphoma | China | 22 Feb 2019 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| CD20 positive Follicular Lymphoma | Phase 3 | - | 01 Oct 2020 | |
| Recurrent Follicular Lymphoma | Phase 3 | - | 01 Oct 2020 | |
| CD20 positive Diffuse Large B-Cell Lymphoma | Phase 3 | China | 01 Oct 2015 | |
| CD20 positive B-Cell Lymphoma | Phase 2 | - | 01 Oct 2014 | |
| CD20 Positive B-Cell Non-Hodgkin Lymphoma | Phase 1 | China | 25 Jun 2015 |
Pubmed Manual | Not Applicable | 33 | ozidmrcgnk(ahteuzcsjt) = vruymqmska byhsolpwwk (ydzbcdrjmg ) View more | Similar | 03 Jul 2022 | ||
ozidmrcgnk(ahteuzcsjt) = lkkczgzfrd byhsolpwwk (ydzbcdrjmg ) View more | |||||||
NCT03522415 (Pubmed) Manual | Phase 3 | 275 | methotrexate+HLX01 | wsygprglrg(hknwkwmjiw) = zkbopljiba qoaaikisnl (jmzaeakloy ) View more | Positive | 10 Jun 2022 | |
methotrexate+Placebo | wsygprglrg(hknwkwmjiw) = upllchzfjt qoaaikisnl (jmzaeakloy ) View more | ||||||
Phase 3 | 407 | CHOP+HLX01 | spfjvugfao(ubzignacdl) = xljpweobai vhlnfpozjn (wlpzbbcdyh ) View more | Similar | 16 Apr 2020 | ||
CHOP+Rituximab | spfjvugfao(ubzignacdl) = mebkajejdn vhlnfpozjn (wlpzbbcdyh ) View more | ||||||
Phase 1/2 | 196 | dolnixxtjg(lsulxhesuf) = rltcmnrqsw ioykxpkdxv (jrgdmlsizy ) View more | - | 24 Nov 2019 |






